Perryllion

Perryllion Therapeutics is a Swiss biotechnology company dedicated to developing transformative therapies for neurodegenerative diseases, with a primary focus on synucleinopathies such as Parkinson's disease. Spun out from the EPFL, the company leverages the pioneering research of Dr. Hilal Lashuel into the molecular mechanisms of protein misfolding and aggregation. Perryllion's approach focuses on targeting specific post-translational modifications and structural polymorphs of alpha-synuclein that drive disease progression. Their pipeline includes small molecule and peptide-based candidates designed to inhibit the formation and spread of toxic protein aggregates in the brain. By addressing the root causes of neurodegeneration, Perryllion aims to provide disease-modifying treatments that significantly improve patient outcomes.